Green CrossㆍCelltrion maintain the 20% level
According to the Korea Exchange, foreign ownership of 36 out of 45 pharmaceutical stocks in the KOSPI market fell in January.
Shin Poong Pharmaceutical, Hyundai Pharmaceutical, Bukwang Pharmaceutical, PharmGen Science, Daewon Pharmaceutical, and Samsung Pharmaceutical lost more than 1%p of foreigner’s stake.
On the other hand, only eight stocks, including Reyon Pharmaceutical, Dong Wha Pharm., Korea United Pharm., Yuyu Pharma, Celltrion, JW Pharmaceutical, Myungmoon Pharmaceutical, and Dongsung Pharmaceutical, gained an increase in foreign ownership during the same period, and the increase remained below 1%p for all.
As foreign stake of pharmaceutical stocks has steadily decreased since last year, the number of stocks that have maintained the 20% level has also dropped to two, Celltrion and Green Cross.
Green Cross’s foreign stake was 23.00%, the highest among the 45 stocks of the pharmaceutical index, followed by Celltrion with 20.67%.
Dong-A St and Kwang Dong Pharmaceutical, which remained at the 20% level until last month, fell to 19.74% and 19.73% and retreated from the 20% level.
Moreover, Yuhan Corporation, Whanin Pharmaceutical, Hanmi Pharmaceutical, Daewon Pharmaceutical, Gene One Life Science, Il-Yang Pharmaceutical, and Samsung Biologics maintained double digits, while Shin Poong Pharmaceutical declined to 9.50%.
In the meantime, Samjin Pharmaceutical, which had close to 40% of foreign ownership before the COVID-19 pandemic, shrank to 8.83%.
Hana Pharm rather expanded foreign investors’ stake from 8.09% last month to 9.18%, larger than that of Samjin Pharmaceutical.
